Aerie Pharmaceuticals Inc. (AERI) Stock Rating Reaffirmed by Cantor Fitzgerald
Aerie Pharmaceuticals Inc. (NASDAQ:AERI)‘s stock had its “buy” rating reiterated by investment analysts at Cantor Fitzgerald in a report released on Saturday. They presently have a $50.00 price target on the stock. Cantor Fitzgerald’s target price would indicate a potential upside of 23.49% from the company’s previous close.
AERI has been the subject of several other reports. Raymond James Financial Inc. started coverage on shares of Aerie Pharmaceuticals in a report on Tuesday, September 13th. They issued an “outperform” rating and a $48.00 price objective for the company. Brean Capital reaffirmed a “buy” rating and issued a $48.00 price objective on shares of Aerie Pharmaceuticals in a report on Wednesday, September 7th. Needham & Company LLC reaffirmed a “buy” rating and issued a $45.00 price objective on shares of Aerie Pharmaceuticals in a report on Tuesday, August 23rd. RBC Capital Markets reaffirmed an “outperform” rating and issued a $55.00 price objective (up from $51.00) on shares of Aerie Pharmaceuticals in a report on Friday, September 16th. Finally, Zacks Investment Research downgraded shares of Aerie Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Tuesday. One analyst has rated the stock with a sell rating and nine have issued a buy rating to the stock. The stock currently has a consensus rating of “Buy” and a consensus target price of $51.40.
Shares of Aerie Pharmaceuticals (NASDAQ:AERI) opened at 40.49 on Friday. Aerie Pharmaceuticals has a 1-year low of $10.82 and a 1-year high of $41.72. The company’s market cap is $1.13 billion. The firm’s 50 day moving average is $28.57 and its 200-day moving average is $19.49.
This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at http://www.americanbankingnews.com/2016/10/08/aerie-pharmaceuticals-inc-aeri-stock-rating-reaffirmed-by-cantor-fitzgerald.html
Aerie Pharmaceuticals (NASDAQ:AERI) last released its quarterly earnings data on Wednesday, August 3rd. The company reported ($0.72) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.74) by $0.02. Equities analysts expect that Aerie Pharmaceuticals will post ($2.81) earnings per share for the current year.
In related news, major shareholder Foresite Capital Fund Ii, L.P. acquired 250,000 shares of the stock in a transaction dated Friday, July 22nd. The shares were purchased at an average price of $17.50 per share, for a total transaction of $4,375,000.00. The acquisition was disclosed in a document filed with the SEC, which is accessible through this link. Insiders own 8.77% of the company’s stock.
Several hedge funds have recently bought and sold shares of the stock. First Mercantile Trust Co. bought a new stake in Aerie Pharmaceuticals during the third quarter valued at $161,000. Schwab Charles Investment Management Inc. boosted its stake in Aerie Pharmaceuticals by 25.8% in the second quarter. Schwab Charles Investment Management Inc. now owns 37,544 shares of the company’s stock valued at $661,000 after buying an additional 7,700 shares during the period. Metropolitan Life Insurance Co. NY boosted its stake in Aerie Pharmaceuticals by 16.6% in the second quarter. Metropolitan Life Insurance Co. NY now owns 17,893 shares of the company’s stock valued at $315,000 after buying an additional 2,544 shares during the period. Iguana Healthcare Management LLC boosted its stake in Aerie Pharmaceuticals by 100.0% in the second quarter. Iguana Healthcare Management LLC now owns 150,000 shares of the company’s stock valued at $2,640,000 after buying an additional 75,000 shares during the period. Finally, Adage Capital Partners GP L.L.C. boosted its stake in Aerie Pharmaceuticals by 3.7% in the second quarter. Adage Capital Partners GP L.L.C. now owns 2,100,000 shares of the company’s stock valued at $36,960,000 after buying an additional 75,000 shares during the period. Hedge funds and other institutional investors own 95.22% of the company’s stock.
Aerie Pharmaceuticals Company Profile
Aerie Pharmaceuticals, Inc is a clinical-stage pharmaceutical company. The Company is engaged in the discovery, development and commercialization of therapies for the treatment of patients with glaucoma and other diseases of the eye. The Company’s primary product candidates are Rhopressa and Roclatan.
Receive News & Ratings for Aerie Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aerie Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.